Price went up $50 this month with no warning - switching vendors — 6 month update

Dr.KarenChen said:

The pattern that distinguishes a bad batch from an exit is behaviour rather than product.

Telehealth prescriber review for cost and coverage: I've used 3 different telehealth platforms to get my GLP-1 prescription. Comparison:

I settled on the one that required labs — it shows they care about safety, not just prescribing volume.

julia.endo said:

Right, and one flattering data point from a group buy is not consistency.

This is exactly what I could not find anywhere else. Sending this to two other people who asked me the same thing last week.

Dr.KarenChen said:

The pattern that distinguishes a bad batch from an exit is behaviour rather than product.

I disagree that testing history is decisive. It tells you what a supplier did when they were being watched. Continuity of behaviour under stress — a late shipment, a failed test, a complaint — is more predictive than any run of good results.

claudia_zurich said:

The list price and the price I actually pay differ by a factor of six depending on which of four routes I use, and none of that is transparent from…

claudia_zurich said:

...regarding the discontinuation data for cost and coverage...

I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."

Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.

This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source.